immunitoAI raises $6.1Mn in Series A round

immunitoAI is a TechBio company developing AI-generated novel antibody therapeutics with pre-defined drug properties. The company has raised $6.1M in its Series A round fund raising.

This round was led by Ashish Kacholia, with participation from 3one4 Capital, AC Ventures, along with the continued support of existing investors – pi Ventures, Anicut Capital, JITO INCUBATION & INNOVATION FOUNDATION, and LVX, JJ Family and Angels.

immunitoAI’s vision is to unleash the full potential of antibody-based biological drugs and make antibody therapy the norm. It’s AI platform generates novel antibody therapeutics with predefined drug characteristics for any protein target, validated through in-house biological methods.

Aridni Shah, Co-Founder and CEO said, “This milestone accelerates our mission to build the world’s most advanced AI-driven antibody discovery and engineering platform, transforming how biologics are designed for every target class — even the undruggable ones. The funds will be dedicated towards building immunitoAI’s drug pipeline utilizing the advanced AI-technology that we have built.”